Peptide-Modified AAV Capsid for Muscle-Specific Gene Transfer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current AAV vectors face challenges in efficiently and selectively transducing muscle tissue after systemic delivery, limiting their effectiveness in gene therapy for muscle diseases.
Innovation Solution
Insertion of a peptide motif RGDLXXL/I into the AAV capsid, specifically targeting the integrin heterodimer αVβ6, enhances muscle transduction efficiency by increasing the affinity and specificity of AAV vectors for muscle tissue.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If AAV vectors are used for systemic delivery to muscle tissue, then gene transfer capability is provided, but transduction efficiency and tissue specificity are insufficient
Solution Approach 1:
The patent applies local quality by inserting a specific peptide motif (RGDLXXL/I) at a defined location within the AAV capsid structure (variable region VIII). This localized modification creates specific binding affinity for integrin αVβ6 receptors on muscle cells, while the rest of the capsid maintains its general function. The peptide insertion at position 587-590 in the VP3 protein sequence provides muscle-targeting capability without altering the overall capsid structure or other tissue interaction properties.
Solution Approach 2:
The patent employs parameter changes by modifying the amino acid sequence of the capsid protein through peptide insertion. Specifically, the RGDLXXL/I motif (where X can be any amino acid) is inserted to create new binding parameters that increase affinity for muscle tissue integrins. This sequence modification changes the biochemical properties of the capsid, enabling selective recognition of muscle cells while maintaining viral assembly and delivery functions.
2Reliability
If AAV capsid is modified with peptide motifs to enhance muscle targeting, then transduction efficiency improves, but capsid structure complexity increases
Solution Approach 1:
The patent applies preliminary action by pre-designing and pre-testing multiple peptide motif variants (RGDLXXL/I where X varies) before selecting the optimal sequence for capsid insertion. The peptide sequence is optimized in advance for integrin binding affinity, and the insertion site is predetermined based on capsid structure analysis. This preliminary optimization ensures that the final capsid construct achieves high muscle targeting efficiency without requiring complex iterative modifications during experimentation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified AAV capsid with the RGDLXXL/I motif achieves at least 1.5-fold higher transduction efficiency in muscle tissue compared to unmodified capsids, improving biodistribution and targeting specificity without increasing off-target tissue uptake.
Implementation Method 1
Insertion of a peptide motif RGDLXXL/I into the AAV capsid, specifically targeting the integrin heterodimer αVβ6, enhances muscle transduction efficiency by increasing the affinity and specificity of AAV vectors for muscle tissue
Data Source
Figure 1A~1B
Figure 2
Figure 3A
AI summary
The invention relates to a peptide-modified AAV capsid having an increased muscle transduction efficiency. The invention relates also to the derived recombinant AAV vector particle packaging a gene of interest, and its use in gene therapy, in particular for treating muscle diseases.